A new inhalable treatment for tuberculosis: Once-weekly nanoparticles match daily oral rifampin in mice

Researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have developed a new inhalable form of tuberculosis (TB) treatment that could significantly reduce the burden of current therapy. Jessica L. Reynolds, Ph.D., associate professor of medicine in the Jacobs School, is senior author on the paper, titled "Repeated Pulmonary Dosing of β-Glucan-Chitosan-PLGA Nanoparticles Controls Mycobacterium Tuberculosis in Mice," published in Antimicrobial Agents and Chemotherapy.